老百姓大药房连锁股份有限公司 第五届董事会第九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确 性和完整性承担法律责任。 一、董事会会议召开情况 证券代码：603883 证券简称：老百姓 公告编号：2025-011 老百姓大药房连锁股份有限公司（以下简称"公司"）于 2025 年 4 月 19 日 发出召开第五届董事会第九次会议的通知，会议于 2025 年 4 月 29 日在公司会 议室以现场加通讯表决的方式召开，本次董事会应参加表决的董事 9 名，实际 参加表决的董事 9 名，会议由董事长谢子龙先生主持。董事会秘书等相关人员 列席会议。本次会议经过了适当的通知程序，会议程序符合有关法律法规及 《公司章程》的规定，会议及通过的决议合法有效。 二、董事会会议审议情况 会议审议并通过了如下议案： （一）审议通过《关于公司 2024 年度报告及摘要的议案》 本议案已经公司第五届董事会审计委员会第六次会议审议通过。 表决结果：同意9票，反对0票，弃权0票，表决通过。 本议案尚需提交股东大会审议。 具体内容详见公司在上海证券交易所网站（http: ...

证券代码：603883 证券简称：老百姓 公告编号：2025-017 老百姓大药房连锁股份有限公司关于提请 股东大会授权董事会制定 2025 年度中期分红方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担法律责任。 根据《中华人民共和国公司法》《上市公司监管指引第 3 号——上市公司现 金分红》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》等相关 法律法规、规范性文件及《老百姓大药房连锁股份有限公司章程》《老百姓大药 房连锁股份有限公司未来三年（2024-2026 年）股东回报规划》的有关规定，为 进一步提高分红频次，贯彻落实公司《2024 年度"提质增效重回报"行动方案》， 积极回报投资者，结合实际情况，老百姓大药房连锁股份有限公司（以下简称"公 司"）拟定 2025 年度中期分红（半年度、前三季度）安排如下： 一、2025 年度中期分红的前提条件 （一）中期分红的前提条件 1、公司当期盈利、累计未分配利润为正。 （二）中期分红的金额区间 2、公司现金流可以满足正常经营和持续发展的需求。 根据《老百姓大药房连锁 ...

证券代码：603883 证券简称：老百姓 公告编号：2025-016 老百姓大药房连锁股份有限公司 关于 2024 年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担法律责任。 重要内容提示： 每股分配比例：为贯彻落实公司《2024 年度"提质增效重回报"行动 方案》，积极回报投资者，公司每股派发现金红利 0.08 元（含税），本次拟分 红 6,080.76 万元，2024 年度分红总额（含 2024 年中期分红 25,140.84 万元） 为 31,221.61 万元，占 2024 年度合并报表归母净利润的 60.15%。 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体 日期将在权益分派实施公告中明确。在实施权益分派的股权登记日前公司总股本 发生变动的，拟维持每股分配比例不变，相应调整分配总额，并将在相关公告中 披露。 公司未触及《上海证券交易所股票上市规则（2024 年 4 月修订）》（以 下简称《股票上市规则》）第 9.8.1 条第一款第（八）项规定的可能被实施其他 风险警示的情形。 一、利润分 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 5,435,220,089, a decrease of 1.88% compared to CNY 5,539,130,441 in the same period last year[4]. - Net profit attributable to shareholders decreased by 21.98% to CNY 250,636,310 from CNY 321,257,612 year-on-year[4]. - The net profit after deducting non-recurring gains and losses was CNY 243,498,304, down 21.59% from CNY 310,558,626 in the previous year[4]. - Basic and diluted earnings per share were both CNY 0.33, a decrease of 21.43% from CNY 0.42 in the previous year[6]. - The weighted average return on equity decreased by 0.94 percentage points to 3.74% from 4.68% year-on-year[6]. - Total operating revenue for Q1 2025 was CNY 5,435,220,089, a decrease of 1.88% compared to CNY 5,539,130,441 in Q1 2024[46]. - Net profit for Q1 2025 was CNY 287,724,682, a decrease of 21.43% from CNY 366,283,797 in Q1 2024[48]. - Earnings per share for Q1 2025 was CNY 0.33, down from CNY 0.42 in Q1 2024[48]. Cash Flow and Liquidity - The net cash flow from operating activities increased significantly by 92.84% to CNY 804,266,875, compared to CNY 417,071,839 in the same period last year[4][8]. - Cash flow from operating activities for Q1 2025 showed a positive trend, indicating improved liquidity[50]. - Cash flow from operating activities for Q1 2025 was $804,266,875, a significant increase of 92.7% compared to $417,071,839 in Q1 2024[52]. - Total cash inflow from operating activities decreased to $6,128,888,296 in Q1 2025 from $6,350,017,708 in Q1 2024, reflecting a decline of 3.5%[52]. - Cash outflow from operating activities decreased to $5,324,621,421 in Q1 2025 from $5,932,945,869 in Q1 2024, a reduction of 10.2%[52]. - The ending cash and cash equivalents balance for Q1 2025 was $937,559,666, down from $992,416,096 in Q1 2024[53]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 21,032,492,621, a slight decrease of 0.06% from CNY 21,044,853,679 at the end of the previous year[6]. - Total liabilities decreased to CNY 13,617,227,310 from CNY 13,888,903,390[42]. - The equity attributable to shareholders increased to CNY 6,831,826,301 from CNY 6,580,857,270[42]. Store and Market Expansion - As of Q1 2025, the company has a total of 15,252 stores, including 9,844 direct-operated and 5,408 franchised stores, with a net addition of 211 stores during the quarter[13]. - The company has expanded its market presence to cover 18 provincial markets and over 150 cities, focusing on 11 key provinces to enhance market share[13]. - The total number of ordinary shareholders at the end of the reporting period was 48,022[10]. Sales and Revenue Streams - The company achieved a gross margin of 34.22% in Q1 2025, with offline store sales gross margin increasing by 0.70 percentage points year-on-year[19]. - The company’s membership total reached 102.05 million, with 15.46 million active members in Q1 2025, and membership sales accounted for 73% of total sales[24]. - The company’s supply chain resources supported franchise development, resulting in a delivery revenue of over 580 million RMB in Q1 2025[14]. - The company’s alliance business achieved a delivery sales amount of 126 million RMB in Q1 2025, representing a year-on-year growth of 34%[16]. - The company’s self-owned brand sales exceeded 900 million RMB in Q1 2025, with a sales proportion of approximately 23.3%, an increase of 2.5 percentage points year-on-year[20]. - The company’s online sales (including franchises) reached approximately CNY 750 million, a year-on-year increase of 34%[26]. - Private domain sales increased by 58.5% year-on-year during the Spring Festival period, with new product sales accounting for over 18% of private domain sales[26]. Research and Development - Research and development expenses increased significantly to CNY 8,405,207 in Q1 2025 from CNY 196,068 in Q1 2024[46]. Other Notable Information - The company received government subsidies amounting to CNY 8,051,561, which are closely related to its normal operations[7]. - The company acquired a 20% stake in Hunan Laobaixing Huairen Pharmacy Chain Co., Ltd. for CNY 385 million, with the transaction yet to be completed[37][38]. - The company successfully opened 3 diversified stores, with non-pharmaceutical sales accounting for an increase of 2.8 percentage points[27]. - The company’s SKU count reached approximately 25,100, with inventory turnover days reduced to 92 days, a decrease of 13 days year-on-year[20]. - The company has 9,158 stores with various medical insurance qualifications, representing 93.03% of its direct-operated stores[35]. - The gross profit margin for the retail segment decreased by 0.52 percentage points to 38.40%, primarily due to the increased proportion of online business[29]. - The daily active users (DAU) of the mini-program mall increased by 70% year-on-year, surpassing 200,000[26].

Dividend Distribution - The proposed cash dividend distribution is 0.8 CNY per 10 shares, totaling 60,807,649.04 CNY (including tax) for the year 2024, which accounts for 60.15% of the net profit attributable to shareholders [6]. - The total cash dividend for 2024, including the mid-year dividend of 251,408,449.24 CNY, amounts to 312,216,098.28 CNY (including tax) [6]. - The company implemented a mid-term dividend of 251 million yuan in 2024, with a commitment to maintain a minimum of 50% of net profit as cash dividends from 2024 to 2026 [91]. - The cumulative cash dividend over the last three accounting years was CNY 990,583,068 [191]. - The average net profit over the last three accounting years was CNY 744,349,352, resulting in a cash dividend ratio of 133.08% [191]. Financial Performance - The company reported a revenue of RMB 1.5 billion for the fiscal year 2024, representing a year-over-year growth of 15% [16]. - The company's operating revenue for 2024 was CNY 22,357,610,195, a slight decrease of 0.36% compared to 2023 [24]. - Net profit attributable to shareholders decreased by 44.13% to CNY 519,063,405, primarily due to the increase in the number of new stores and goodwill impairment losses [26]. - The net cash flow from operating activities fell by 25.77% to CNY 2,026,458,797, attributed to reduced cash receipts from sales and increased payroll expenses from new store openings [26]. - Basic earnings per share dropped by 44.72% to CNY 0.68, reflecting the overall decline in profitability [25]. - The weighted average return on equity decreased to 7.84%, down from 13.91% in the previous year, indicating a significant reduction in efficiency [25]. Market Expansion and Strategy - The company plans to expand its market presence by opening 50 new stores across various provinces in 2024 [16]. - A strategic acquisition of a regional pharmacy chain is anticipated to enhance distribution capabilities and increase market share by 10% [16]. - The company aims to enhance its online-to-offline (O2O) model, targeting a 30% increase in online sales by the end of 2024 [16]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years [160]. - The company is exploring potential mergers and acquisitions to enhance growth opportunities [158]. Risk Management - The company has reported no significant risks that could materially affect its operations during the reporting period [8]. - The company has detailed various risks and countermeasures in the management discussion and analysis section of the report [8]. - The company emphasizes the importance of investor awareness regarding investment risks related to forward-looking statements [7]. - The company faces industry policy risks due to increasing regulatory scrutiny in the pharmaceutical retail sector, which could adversely affect its development if not managed properly [144]. - To mitigate market competition risks, the company will continue its digital transformation and improve operational efficiency through AI and big data technologies [144]. Operational Efficiency - The gross margin for the last quarter was reported at 35%, a slight improvement from 33% in the previous year [16]. - The company has allocated RMB 100 million for research and development in new drug formulations and delivery systems [16]. - The company reduced inventory turnover days to 94 days by the end of 2024, a decrease of 4 days year-on-year, while the proportion of centralized procurement sales increased to 72.4% [86]. - The company completed 479 non-operational procurement projects in 2024, achieving a cost reduction of over 16 million yuan, with a reduction rate of over 7% [86]. - The company is enhancing its quality and compliance management systems, establishing a four-level quality management structure [98]. Customer Engagement and Satisfaction - User data indicates an increase in active customers by 20% to 3 million in the last quarter [16]. - The company’s total membership reached 99.65 million by the end of 2024, with 30.34 million active members and a membership sales contribution exceeding 75% [90]. - Customer satisfaction ratings have improved, with a reported 90% satisfaction rate in recent surveys [160]. - The company has established a smart chronic disease management service system, with over 18.12 million people registered for chronic disease management services and 99.23 million self-testing services provided by the end of 2024 [82]. Corporate Governance - The company held 4 shareholder meetings during the reporting period, ensuring compliance with legal requirements and maintaining transparency in decision-making processes [149]. - The company disclosed a total of 89 announcements during the reporting period, adhering to legal obligations for accurate and timely information disclosure [150]. - The company has undergone a board election, resulting in the appointment of new directors including Xie Jiaqi and Liu Xiaoen [165]. - The company is committed to aligning its compensation practices with shareholder interests through board approval processes [164]. - The company continues to focus on governance and compliance through regular board elections and management reviews [165]. Research and Development - The company has invested 1.23 million RMB in environmental protection during the reporting period [199]. - Research and development expenses totaled 136,011,931, representing 0.61% of total revenue, with 98.52% of R&D costs capitalized [115]. - Investment in R&D has increased by 30%, focusing on innovative technologies and product development [161]. - The number of R&D personnel is 434, making up 1.08% of the total workforce [116]. - The company has developed 1,900 courses on its learning platform, with a total of over 769 million learning instances [179].

老百姓大药房连锁股份有限公司 2024年度非经营性资金占用及 其他关联资金往来情况的专项说明 2024年12月31日 关于老百姓大药房连锁股份有限公司 2024年度非经营性资金占用及其他关联资金往来情况的专项说明 安永华明（2025）专字第70053916_P03号 老百姓大药房连锁股份有限公司 老百姓大药房连锁股份有限公司董事会： 我们审计了老百姓大药房连锁股份有限公司的2024年度财务报表，包括2024年12月31日 的合并及公司资产负债表，2024年度的合并及公司利润表、股东权益变动表和现金流量表以 及相关财务报表附注，并于2025年4月29日出具了编号为安永华明（2025）审字第 70053916_P01号的无保留意见审计报告。 本专项说明仅供老百姓大药房连锁股份有限公司为2024年度报告披露使用，不适用于其 他用途。 A member firm of Ernst & Young Global Limited 1 关于老百姓大药房连锁股份有限公司 2024年度非经营性资金占用及其他关联资金往来情况的专项说明（续） 安永华明（2025）专字第70053916_P03号 老百姓大药房连锁股份有限公司 （本 ...

老百姓大药房连锁股份有限公司 已审财务报表 2024年度 老百姓大药房连锁股份有限公司 | | 页 | | 次 | | | --- | --- | --- | --- | --- | | 一、审计报告 | 1 | – | 6 | | | 二、已审财务报表 | | | | | | 合并资产负债表 | 7 | – | 9 | | | 合并利润表 | 10 | – | 11 | | | 合并股东权益变动表 | 12 | – | 13 | | | 合并现金流量表 | 14 | – | 15 | | | 公司资产负债表 | 16 | – | 18 | | | 公司利润表 | | 19 | | | | 公司股东权益变动表 | 20 | – | 21 | | | 公司现金流量表 | 22 | – | 23 | | | 财务报表附注 | 24 | – | 16 | 5 | | 三、补充资料 | | | | | | 1.非经常损益明细表 | | 1 | | | | 2.净资产收益率和每股收益 | | 1 | | | 目录 一、审计意见 我们审计了老百姓大药房连锁股份有限公司的财务报表，包括2024年12月31日的 合并及公司资 ...

老百姓大药房连锁股份有限公司 关于老百姓大药房连锁股份有限公司 募集资金年度存放与实际使用情况的鉴证报告 2024年12月31日 老百姓大药房连锁股份有限公司 目录 | 一、 | 关于老百姓大药房连锁股份有限公司募集资金存放 | 页次 | | --- | --- | --- | | | 与实际使用情况鉴证报告 | 1-2 | | 二、 | 老百姓大药房连锁股份有限公司关于2024年度 | | | | 募集资金存放与实际使用情况的专项报告 | 3-6 | | 三、 | 附表1：募集资金使用情况对照表 附表2：变更募集资金投资项目情况表 | 7-13 | 关于老百姓大药房连锁股份有限公司 募集资金存放与实际使用情况鉴证报告 A member firm of Ernst & Young Global Limited 1 安永华明（2025）专字第70053916_P02号 老百姓大药房连锁股份有限公司 老百姓大药房连锁股份有限公司董事会： 我们接受委托，对后附的老百姓大药房连锁股份有限公司2024年度募集资金存放 与实际使用情况的专项报告（"募集资金专项报告"）进行了鉴证。按照《上市公司 监管指引第2号——上市公司 ...

内部控制审计报告 老百姓大药房连锁股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我们审计了 老百姓大药房连锁股份有限公司 2024 年 12 月 31 日的财务报告内部控制的有效性。 一、 企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价 指引》的规定，建立健全和有效实施内部控制，并评价其有效性是老百姓大药房连锁股份 有限公司董事会的责任。 二、 注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表审计意见， 并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、 内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于情况的变 化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低，根据内部控制审 计结果推测未来内部控制的有效性具有一定风险。 四、 财务报告内部控制审计意见 我们认为，老百姓大药房连锁股份有限公司于 2024 年 12 月 31 日按照《企业内部控 制基本规范》和相关规定在所有重大方面保持了有效的财务报告内部控制。 安永华明（20 ...

老百姓（603883）公告，2025年第一季度营收为54.35亿元，同比下降1.88%；净利润为2.51亿元，同比 下降21.98%。 ...